The EU medicines agency EMA has given the green light to the first RSV vaccine for babies. It is designed to protect both pregnant women and newborns up to six months old. However, Abrysvo is also recommended for adults over 60 years old.
Respiratory syncytial virus (RSV) causes respiratory illnesses that are mild in most cases. However, it can also be serious or even fatal in young children and frail older adults. Another new vaccine – Arexvy – was approved in June for people 60 and older. According to the Paul Ehrlich Institute, there are about 250,000 hospitalizations and 17,000 deaths in this category each year.
The green light was also given in Amsterdam on Friday for the Abrysvo vaccine. This is the first to also protect babies up to six months. In pregnant women, the antibodies penetrate the placenta and protect the child for up to six months after birth, according to the EMA.
pain at the injection site
The most common side effects in pregnant women were injection site pain, headache and myalgia. There was also pain at the vaccination site in people over 60 years of age. For the new vaccine to be approved, the European Commission still needs to approve it.
Source: Krone
I am Wallace Jones, an experienced journalist. I specialize in writing for the world section of Today Times Live. With over a decade of experience, I have developed an eye for detail when it comes to reporting on local and global stories. My passion lies in uncovering the truth through my investigative skills and creating thought-provoking content that resonates with readers worldwide.
